
Sponsored
Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.
By Rajiv Nayar and Mark C. Manning, HTD Biosystms, Inc., pp. 20-28. Outsourcing is often considered a way to expedite drug development, but other options exist for companies that don't choose it yy} or that run up against the capacity shortage. The resources devoted to speeding up the drug discovery process led to combinatorial libraries, high-throughput screening, proteomics, and genomics. Now the same types of innovation can be applied to drug development to prevent valuable lead compounds from sitting idle on the shelf.
over 24 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 24 years ago
The Immunogenicity of Therapeutic Proteinsover 24 years ago
Inside Washington: Costs and Controls Challenge Manufacturersover 24 years ago
21 CFR Part 11: (Un)Expected Added Value